£138.18
1.54%
London, Nov 17, 12:17 pm GMT. Market open.
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

£140.34
+15.88 12.76% 1M
+4.15 3.04% 6M
+4.76 3.51% YTD
+6.70 5.02% 1Y
+44.61 46.59% 3Y
+62.83 81.05% 5Y
+107.47 326.89% 10Y
+125.99 877.87% 20Y
London, Closing price Mon, Nov 16 2026
+0.52 0.37%

AI Insights on AstraZeneca Insights AI Insights on AstraZeneca

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is AstraZeneca a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
£216.8b
Enterprise Value
£236.3b
Net debt
£19.5b
Cash
£6.2b
Shares outstanding
1.6b
Valuation
P/E
26.2
P/S | estimate
4.6 | 4.4
EV/Sales | estimate
5.0 | 4.8
EV/FCF | ex SBC
51.1 | -
P/B
5.5
Dividends
DPS
£2.36
Yield 1Y | 5Y
1.7% | 2.4%
Growth 1Y | 5Y
-3.8% | 2.7%
Payout 1Y | 3Y
47.5% | 63.0%
Increased
0 Years
Financials
Revenue | estimate
£47.3b | £49.3b
EBITDA
£15.3b
EBIT
£12.1b
Net Income
£8.4b
Free Cash Flow | ex SBC
£4.6b | -
Growth
Revenue | estimate
7.3% | 10.8%
EBITDA
10.6%
EBIT
12.5%
Net Income
17.4%
Free Cash Flow
-36.3%
Margin
Gross
81.7%
EBITDA
32.3%
EBIT
25.5%
Net
17.7%
Free Cash Flow | ex SBC
9.8% | -
Financial Health
Equity Ratio
42.7%
Return on Equity
21.0%
ROCE
18.0%
ROIC
15.4%
Debt/Equity
0.7
More
EPS
£5.4
FCF per Share
£3.0
Short interest
426.0%
Employees
96k
Rev per Employee
£460.0k

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

28x Buy
82%
6x Hold
18%

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

Buy
82%
Hold
18%

AstraZeneca Events

Past Events
OCT
30
Q3 2026 Earnings Call
18 days ago
OCT
12
American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting
about one month ago
SEP
8
European Respiratory Society (ERS) Congress
2 months ago
JUL
27
Q2 2026 Earnings Call
4 months ago
JUL
6
Special Call - AstraZeneca PLC
4 months ago
APR
29
Q1 2026 Earnings Call
7 months ago
FEB
10
Q4 2025 Earnings Call
9 months ago
JAN
11
44th Annual J.P. Morgan Healthcare Conference
10 months ago
NOV
6
Q3 2025 Earnings Call
about one year ago

Financial data from AstraZeneca

Sep '26
+/-
%
47,304 47,304
7% 7%
100%
- Direct Costs 8,668 8,668
9% 9%
18%
38,636 38,636
7% 7%
82%
- Selling and Administrative Expenses 12,766 12,766
6% 6%
27%
- Research and Development Expense 11,204 11,204
8% 8%
24%
15,278 15,278
11% 11%
32%
- Depreciation and Amortization 3,208 3,208
4% 4%
7%
EBIT (Operating Income) EBIT 12,071 12,071
13% 13%
26%
Net Profit 8,364 8,364
17% 17%
18%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Negative
Barrons
●
about 23 hours ago
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
Neutral
Business Wire
●
4 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's ​IMFINZI® (durvalumab)​ in combination with enfortumab vedotin-ejfv (EV) as neoadjuvant treatment, followed by IMFINZI monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have...
Negative
Reuters
●
4 days ago
AstraZeneca has cut about 600 ​jobs from its respiratory and ‌immunology commercial teams in the US as part of its three-year cost-savings initiative, ​Bloomberg News reported on Friday, citing ​people familiar with the matter.
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Mr. Soriot
Employees 96,100
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today